Ocular hypertension in children treated with brimonidine 0.2%. A clinical study;Tratamiento de la hipertensión ocular infantil con colirio de brimonidina 0,2%

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 81, Issue 3, 2006, Pages 155-160

  Montero De Espinosa, I ^a   Marquez De Aracena R ^a   Morales, C ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Brimonidinc; Glaucoma; Ocular hypertension; Paediatric

Indexed keywords

ANTIHYPERTENSIVE AGENT; BRIMONIDINE; QUINOXALINE DERIVATIVE;

ARTICLE; CHILD; COMPARATIVE STUDY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; RETROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANTIHYPERTENSIVE AGENTS; CHILD; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; QUINOXALINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33750115972     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Korsch E, Grote A, Seybold M, Soditt V. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma. Eur J Pediatr 1999; 158: 685.
2. Berlin R, Sing K, Lee U, Steiner R. Toxicity from use of brimonidine ophthalmic solution in an infant and reversal with naloxone. J Toxicol Clin Toxicol 1997; 35: 506.
3. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS 2001; 5: 281-284.
4. Carlsen JO, Zabriskie NA, Kwon YH, Barbe ME, Scott WE. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 1999; 128: 255-256.
5. Berlin RJ, Lee UT. Samples JR, Rich LF, Tang-Liu DD, Sing KA, et al. Ophthalmic drops causing coma in an infant. J Pediatr 2001; 138: 441-443.
6. Bateman DN, Clark R, Azuara-Blanco A, Bain M, Forrest J. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care. Br J Ophthalmol 2002; 86: 551-554.
7. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999; 127: 20-26.
8. Derick RJ, Robin AL, Walters TR, Barnebey HS, Chaplin N, Schuman J, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997; 104: 131-136.
9. Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 131: 631-635.
10. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998; 105: 1960-1967.
11. Rolle T, Cipullo D, Vizzeri GM, Triggiani A, Brogliatti B. Evaluation and comparison between the effects on intraocular pressure and retinal blood flow of two antiglaucomaloits drugs administered in monotherapy: brimonidine and latanoprost. Preliminary results. Acta Ophthalmol Scand Suppl 2000; 232: 50-52.
12. Slewarl WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol 2001; 131: 798-799.
13. Sponsel WE, Paris G, Trigo Y, Pena M, Weber A, Sanford K, et al. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroideal anti-inflammatory therapy. Am J Ophthalmol 2002; 133: 11-18.
14. Chen TC, Ang RT, Grosskreutz CI, Pasquale LR, Fan JT. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery. Ophthalmology 2001; 108: 1033-1038.
15. Kasahara N. Brimonidine 0.2% to prevent post laser IOP elevation (letter). Ophthalmology 2002; 109: 828-829.
16. Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol 2000; 130: 287-291.
17. Siewart WC, Stewart JA, Jackson AL. Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. Acta Ophthalmol Scand 2002; 80: 277-281.
18. Stewart WC, Sharps ED, Harbin TS Jr, Pastor SA, Day DG, Holmes KT, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressitre. Am J Ophthalmol 2000; 129: 723-727.
19. Scruggs JT, Whiteside-Michel J, Brodsky MC. The teardrop sign: a rare dermatological reaction to brimonidine. Br J Ophthalmol 2000; 84: 671-672.
20. Zimmerman TJ, Kooner KS, Morgan KS. Safety and efficacy of timolol in pediatric glaucoma. Surv Ophthalmol 1983; 28: 262-264.